Literature DB >> 2466788

Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells.

B C Berk1, V Vekshtein, H M Gordon, T Tsuda.   

Abstract

To investigate the role of vasoconstrictor hormones in vascular smooth muscle cell growth we have studied the effects of the potent vasoconstrictor angiotensin II on cell growth in a cultured rat aortic cell model. Angiotensin II was not mitogenic for these cells, as assessed by determining cell number, nor was it synergistic in this regard with 10% calf serum. However, 24-hour exposure to 100 nM angiotensin II caused an 80% increase in protein synthesis (compared with 0.4% increase with serum control) as measured by tritiated leucine incorporation. This was a "hypertrophic" response as indicated by a 30% increase in protein content and a 45% increase in cell volume. Angiotensin II-induced smooth muscle cell hypertrophy was maximal at 100 nM, had an ED50 of 1 nM, and was inhibited by the competitive antagonist [Sar1, Ile8]angiotensin II. The increase in protein synthesis required continuous presence of angiotensin II for 6 hours and required messenger RNA (mRNA) synthesis as suggested by complete inhibition after exposure to actinomycin D. Angiotensin II-stimulated protein synthesis was dependent on a rise in intracellular Ca2+ concentration evidenced by a 70% decrease in tritiated leucine incorporation after chelation of Ca2+ with 25 microM quin 2-AM. This treatment did not alter protein synthesis induced by 10% calf serum. Decreasing extracellular Na+ to prevent Na+/H+ exchange and intracellular alkalinization did not inhibit the angiotensin II response but decreased the 10% calf serum-stimulated protein synthesis by 35%. Downregulation of protein kinase C by 24-hour treatment with phorbol 12,13-dibutyrate did not inhibit angiotensin II-induced protein synthesis, while phorbol 12-myristate 13-acetate-stimulated protein synthesis was abolished. These findings suggest that angiotensin II-induced hypertrophy, acting via a Ca2+ mechanism, may play an important role in abnormal vascular smooth muscle cell growth in certain forms of hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466788     DOI: 10.1161/01.hyp.13.4.305

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  65 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis.

Authors:  B L Webb; S J Hirst; M A Giembycz
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

3.  FoxO1 mediates an autofeedback loop regulating SIRT1 expression.

Authors:  Shiqin Xiong; Gloria Salazar; Nikolay Patrushev; R Wayne Alexander
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

Review 4.  Acute and chronic regulation of aldosterone production.

Authors:  Namita G Hattangady; Lawrence O Olala; Wendy B Bollag; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2011-08-04       Impact factor: 4.102

Review 5.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 6.  Angiotensin II-receptor antagonist in the treatment of hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Erika Pagannone
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

7.  Angiotensin-converting enzyme genotype affects skeletal muscle strength in elite athletes.

Authors:  Aldo Matos Costa; António José Silva; Nuno Garrido; Hugo Louro; Daniel Almeida Marinho; Mário Cardoso Marques; Luiza Breitenfeld
Journal:  J Sports Sci Med       Date:  2009-09-01       Impact factor: 2.988

Review 8.  Should we aim at tissue renin-angiotensin systems?

Authors:  J F Smits; R C Passier; M J Daemen
Journal:  Pharm World Sci       Date:  1998-06

Review 9.  The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides.

Authors:  A M Richards
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

10.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.